Methods and systems for large spot retinal laser treatment

US11318048B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11318048-B2
Application numberUS-201916556827-A
CountryUS
Kind codeB2
Filing dateAug 30, 2019
Priority dateAug 31, 2018
Publication dateMay 3, 2022
Grant dateMay 3, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

In some embodiments, a system for providing a therapeutic treatment to a patient's eye includes a treatment beam source configured to transmit a treatment beam along a treatment beam path. The system further includes a processor coupled to the treatment beam source, the processor being configured to direct the treatment beam onto retinal tissue of the patient's eye and deliver a series of short duration pulses from the treatment beam onto the retinal tissue at a first treatment spot to treat the retinal tissue. In some embodiments, a pre-treatment evaluation method using electroretinography (ERG) data may be used to predict effects of treatment beams at different power values and to determine optimal power values.

First claim

Opening claim text (preview).

What is claimed is: 1. A system for providing a therapeutic treatment to a patient's eye, the system comprising: a treatment beam source configured to transmit a treatment beam along a treatment beam path, the treatment beam having an infrared wavelength and a power from 1 to 100 W; an aiming beam source configured to transmit an aiming beam along an aiming beam path, the aiming beam having a visible wavelength and the aiming beam path extending non-coaxially relative to the treatment beam path; and a processor coupled to the treatment beam source and the aiming beam source, the processor being configured to: direct the aiming beam onto the retinal tissue of the patient's eye at a first treatment spot and define, via the aiming beam, a treatment boundary surrounding the first treatment spot such that the first treatment spot is disposed therein; direct the treatment beam onto retinal tissue of the patient's eye; and deliver a series of pulses from the treatment beam onto the retinal tissue at the first treatment spot to treat the retinal tissue, the first treatment spot being 1 to 6 mm in diameter, wherein: a duration of each pulse is sufficiently short so as to avoid inducing photocoagulation of the retinal tissue that results in visible tissue damage; and the series of pulses directed to the first treatment spot induces photoactivation of a therapeutic healing at the first treatment spot. 2. The system of claim 1 , wherein the treatment beam is configured to be directed onto the retinal tissue of the patient's eye to ensure substantially uniform tissue heating at the treatment spot without being scanned. 3. The system of claim 1 , wherein the treatment beam source is a vertical-cavity surface-emitting laser (VCSEL). 4. The system of claim 1 , wherein the treatment beam source is configured to be located above the patient to transmit the treatment beam in a generally downward direction toward the patient's eye such that the patient may be in a supine position during treatment. 5. The system of claim 1 , wherein the first treatment spot comprises a macular region of the retinal tissue. 6. The system of claim 5 , wherein the treatment beam is configured to be directed onto 80 to 100% of the macular region. 7. The system of claim 1 , wherein the treatment beam heats the retinal tissue at the first treatment spot in a range of 50 to 55 degrees C. 8. The system of claim 1 , wherein the treatment boundary comprises at least one of a ring or circular cross-section. 9. The system of claim 1 , wherein the aiming beam has a power under 1 mW. 10. The system of claim 1 , further comprising a convex lens disposed between the patient and the aiming beam source configured to focus the aiming beam onto a concentric ring on the retinal tissue surrounding the treatment beam at the first treatment spot. 11. The system of claim 10 , wherein the treatment beam source is disposed between the convex lens and the aiming beam source. 12. The system of claim 11 , further comprising a concave lens disposed between the aiming beam source and the treatment beam source configured to diverge the aiming beam around the treatment beam source such that only a portion of the aiming beam is blocked by the treatment beam source. 13. The system of claim 1 , wherein the aiming beam is directed onto a retinal pigment epithelium of the patient's eye. 14. A method for providing a therapeutic treatment to a patient's eye, the method comprising: delivering an aiming beam from an aiming beam source along an aiming beam path, the aiming beam having a visible wavelength and the aiming beam path extending non-coaxially relative to a treatment beam path; directing the aiming beam onto the retinal tissue of the patient's eye at a treatment spot defining, via the aiming beam, a treatment boundary surrounding the treatment spot such that the treatment spot is disposed therein; and delivering, via the treatment beam from the treatment beam source, a therapeutic treatment to retinal tissue of the patient's eye, the delivered therapeutic treatment comprising the treatment spot on the retinal tissue at an intensity below that which effects coagulative damage so as to minimize damage to the retinal tissue, the treatment beam being delivered at an infrared wavelength, and along the treatment beam path and the treatment spot being 1 to 6 mm in diameter. 15. The method of claim 14 , further comprising delivering a series of pulses from the treatment beam onto the retinal tissue at the treatment spot to therapeutically treat the retinal tissue, wherein a duration of each pulse is sufficiently short so as to avoid inducing photocoagulation of the retinal tissue that results in visible tissue damage, and wherein the series of pulses directed to the treatment spot induces photoactivation of a therapeutic healing at that treatment spot. 16. The method of claim 14 , wherein the therapeutic treatment is delivered only to a single treatment spot on the retinal tissue. 17. The method of claim 14 , further comprising heating the tissue at the treatment spot in a substantially uniform manner without scanning the treatment beam. 18. The method of claim 14 , wherein the treatment beam source comprises a VCSEL array, the VCSEL array comprising a set of laser-delivery elements that are individually powered, wherein delivering the treatment beam to the treatment spot comprises: delivering, by the laser-delivery elements, a plurality of laser beams to a plurality of sub-spots within the treatment spot, wherein laser outputs of the laser-delivery elements are individually adjusted so as to ensure substantially uniform tissue heating at the treatment spot. 19. The method of claim 14 , further comprising delivering the therapeutic treatment via a generally downward treatment beam path toward the patient's eye such that the patient may be in a supine position during treatment. 20. The method of claim 14 , wherein the treatment spot comprises a macular region of the retinal tissue. 21. The method of claim 20 , further comprising delivering the therapeutic treatment onto 80 to 100% of the macular region. 22. The method of claim 14 , wherein directing the aiming beam onto the retinal tissue comprises directing the aiming beam through a convex lens disposed between the patient and the aiming beam source to focus the aiming beam onto a concentric ring on the retinal tissue surrounding the treatment spot. 23. The method of claim 22 , wherein the treatment beam source is disposed between the convex lens and the aiming beam source. 24. The method of claim 23 , wherein directing the aiming beam onto the retinal tissue comprises directing the aiming beam through a concave lens disposed between the aiming beam source and the treatment beam source to diverge the aiming beam around the treatment beam source such that only a portion of the aiming beam is blocked by the treatment beam source prior to directing the aiming beam through the convex lens. 25. The method of claim 14 , wherein delivering the treatment beam onto the retinal tissue comprises delivering a series of pulses onto a retinal pigment epithelium at the treatment spot to therapeutically treat the retinal tissue, wherein a duration of each pulse is sufficiently short to allow tissue cooling between pulses which limits a temperature increase at the tissue and avoids inducing photocoagulation of the retinal tissue that results in visible tis

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11318048B2 cover?
In some embodiments, a system for providing a therapeutic treatment to a patient's eye includes a treatment beam source configured to transmit a treatment beam along a treatment beam path. The system further includes a processor coupled to the treatment beam source, the processor being configured to direct the treatment beam onto retinal tissue of the patient's eye and deliver a series of short…
Who is the assignee on this patent?
Iridex Corp
What technology area does this patent fall under?
Primary CPC classification A61F9/008. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).